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The systemic and resistant nature of neuroblastoma metastasized to distant organs makes it largely incurable with 
current multimodal treatment. Clinical progression stems mainly from an increasing burden of metastatic 
colonization. Novel therapeutic perspectives may be won by blocking as yet poorly understood pathways triggering 
the migration-invasion-metastasis cascade in neuroblastoma. The CD9 cell surface glycoprotein was decoded as a 
major downstream player and direct target of the recently described GRHL1 tumor suppressor in in-depth 
transcriptome analyses and ChIP-qRT-PCR. CD9 is known to facilitate carcinoma cell motility and metastasis. 
High-level CD9 expression in primary neuroblastomas correlated with patient survival and established markers for 
favorable disease. Low-level CD9 expression was an independent risk factor for adverse outcome and predicted 
poor treatment response in patients with the worst outcome. MYCN and HDAC5 co-localized to the CD9 promoter 
and repressed transcription. CD9 expression was strongly reduced during progressive development of murine 
tumors in the TH-MYCN transgenic mouse model of neuroblastoma compared to expression in ganglia from 
wildtype mice, further supporting MYCN involvement in CD9 transcriptional repression in neuroblastoma cells. 
We detected differential CD9 methylation in 450K methylation array analyses of primary neuroblastomas, and 
CD9 hypermethylation was associated with reduced CD9 expression, supporting epigenetic regulation. Inducing 
CD9 expression in a SH-EP cell model inhibited migration and invasion in Boyden chamber assays. Enforced CD9 
expression in neuroblastoma cells transplanted onto chicken chorioallantoic membranes strongly reduced 
metastasis to chicken embryo bone marrow. Combined treatment of neuroblastoma cells with inhibitors for 
HDACs and DNA methyltransferase induced CD9 expression. Our results show CD9 is a critical and indirectly 
druggable mediator of neuroblastoma cell invasion and metastasis. 
